- Home
- CRDF vs AGEN Comparison
CRDF vs AGEN Comparison
Compare CRDF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- AGEN
- Stock Information
- Founded
- CRDF 1999
- AGEN 1994
- Country
- CRDF United States
- AGEN United States
- Employees
- CRDF N/A
- AGEN N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDF Health Care
- AGEN Health Care
- Exchange
- CRDF Nasdaq
- AGEN Nasdaq
- Market Cap
- CRDF 144.4M
- AGEN 123.6M
- IPO Year
- CRDF N/A
- AGEN 2000
- Fundamental
- Price
- CRDF $2.22
- AGEN $4.19
- Analyst Decision
- CRDF Strong Buy
- AGEN Buy
- Analyst Count
- CRDF 5
- AGEN 2
- Target Price
- CRDF $11.10
- AGEN $14.50
- AVG Volume (30 Days)
- CRDF 859.9K
- AGEN 466.1K
- Earning Date
- CRDF 11-06-2025
- AGEN 11-11-2025
- Dividend Yield
- CRDF N/A
- AGEN N/A
- EPS Growth
- CRDF N/A
- AGEN N/A
- EPS
- CRDF N/A
- AGEN N/A
- Revenue
- CRDF $545,000.00
- AGEN $101,706,000.00
- Revenue This Year
- CRDF N/A
- AGEN $60.49
- Revenue Next Year
- CRDF N/A
- AGEN N/A
- P/E Ratio
- CRDF N/A
- AGEN N/A
- Revenue Growth
- CRDF N/A
- AGEN N/A
- 52 Week Low
- CRDF $1.90
- AGEN $1.38
- 52 Week High
- CRDF $5.64
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- CRDF 50.17
- AGEN 48.01
- Support Level
- CRDF $2.10
- AGEN $4.00
- Resistance Level
- CRDF $2.33
- AGEN $4.60
- Average True Range (ATR)
- CRDF 0.12
- AGEN 0.24
- MACD
- CRDF 0.01
- AGEN 0.04
- Stochastic Oscillator
- CRDF 37.82
- AGEN 45.76
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).